These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26371595)

  • 1. Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation.
    Caston JJ; Castells L; Varo E; Gomez MA; de la Mata M; Campos-Varela I; Lumbreras C; Gonzalez-Dieguez L; Fabregat J; Herrero I; Salcedo M; Sanchez-Antolín G; Torre-Cisneros J
    Transplantation; 2016 Mar; 100(3):593-9. PubMed ID: 26371595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation.
    Bosch W; Heckman MG; Pungpapong S; Diehl NN; Shalev JA; Hellinger WC
    Transplantation; 2012 Apr; 93(7):723-8. PubMed ID: 22406819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
    García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
    Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
    Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
    J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
    Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
    Natori Y; Humar A; Husain S; Rotstein C; Renner E; Singer L; Kim SJ; Kumar D
    Transplantation; 2017 Jun; 101(6):1449-1454. PubMed ID: 27467535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation.
    Nebbia G; Mattes FM; Cholongitas E; Garcia-Diaz A; Samonakis DN; Burroughs AK; Emery VC
    Liver Transpl; 2007 Jan; 13(1):130-5. PubMed ID: 17192909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and extended therapy for recurrent hepatitis C after liver transplantation.
    García-Pajares F; Almohalla C; Lorenzo Pelayo S; Ruiz Zorrilla R; Pinto P; Ramos C; Sanchez Antolin G; Paton AC
    Transplant Proc; 2012; 44(6):1571-3. PubMed ID: 22841217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
    Solidoro P; Patrucco F; Libertucci D; Verri G; Sidoti F; Curtoni A; Boffini M; Simonato E; Rinaldi M; Cavallo R; Costa C
    Ther Adv Respir Dis; 2019; 13():1753466619878555. PubMed ID: 31566097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays.
    Rahman W; Tu T; Budzinska M; Huang P; Belov L; Chrisp JS; Christopherson RI; Warner FJ; Bowden DS; Thompson AJ; Bowen DG; Strasser SI; Koorey D; Sharland AF; Yang JY; McCaughan GW; Shackel NA
    Transplantation; 2015 Sep; 99(9):e120-6. PubMed ID: 25706280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation.
    Humar A; Kumar D; Raboud J; Caliendo AM; Moussa G; Levy G; Mazzulli T
    Am J Transplant; 2002 May; 2(5):461-6. PubMed ID: 12123213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The recurrence of hepatitis C virus after liver transplantation].
    Nemes B; Sárváry E; Gerlei Z; Fazakas J; Doros A; Németh A; Görög D; Fehérvári I; Máthé Z; Gálffy Z; Pár A; Schuller J; Telegdy L; Fehér J; Lotz G; Schaff Z; Nagy P; Járay J; Lengyel G
    Orv Hetil; 2007 Oct; 148(42):1971-9. PubMed ID: 17932003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.